Efficacy of melflufen in multiple myeloma with mutated or deleted TP53. [PDF]
Acs K +20 more
europepmc +1 more source
DNTTIP1 drives leukaemogenesis through MiDAC‐mediated epigenetic silencing of BMF
DNTTIP1 cooperates with SP1 to recruit HDAC1/2, leading to BMF silencing and reduced competitive binding of BMF to BCL2.This suppresses autophagy and apoptosis, promoting leukaemic cell survival. Targeting the DNTTIP1‐HDAC1/2‐BMF axis reactivates BMF and induces anti‐leukaemic effects.
Ruolin Xiu +12 more
wiley +1 more source
Hypoxia promotes BCMA loss and a suppressive secretome thereby hindering CAR T cell therapy in multiple myeloma. [PDF]
Tu C +9 more
europepmc +1 more source
(1) Core Process: Persistent antigen, from TDLNs to TME, drives Tpex → Tex‐int → Tex‐term differentiation. (2) Multiomics Regulation: This fate transition is orchestrated by a co‐ordinated, multi‐layered molecular network. (3) Functional Outcome: Dysregulated signalling and surging co‐inhibitory receptors lock in proliferative arrest and functional ...
Tong Zhu +5 more
wiley +1 more source
Not All Bone Lesions After Breast Cancer Treatment Indicate Metastasis: A Case Report and Review of the Literature. [PDF]
Kaakoua M +7 more
europepmc +1 more source
Solitary Bone Plasmacytoma of the Scapula: A Rare Localization With Remarkable Radiotherapy Outcome. [PDF]
El Mjabber R +7 more
europepmc +1 more source
Concomitant Transthyretin Amyloid Cardiomyopathy in Patients With Multiple Myeloma. [PDF]
Ibrahim M +9 more
europepmc +1 more source
Daratumumab monotherapy in a patient with kappa light chain multiple myeloma and decompensated cirrhosis: a case report. [PDF]
Yang X +5 more
europepmc +1 more source
Rethinking surgical intervention in the multidisciplinary comprehensive management of craniocerebral metastasis in multiple myeloma. [PDF]
Shen J, Cai Y, Ouyang H, Zhong X.
europepmc +1 more source

